Related Experiment Video
Updated: Jun 30, 2026

Parasite Induced Genetically Driven Autoimmune Chagas Heart Disease in the Chicken Model
Published on: July 29, 2012
Identification of chicken-derived antibodies targeting the Candida albicans Als3 protein
Chi-Hsin Lee1,2,3, Chao-Jung Wu1,2, Fang-Yi Yen1
1School of Medical Laboratory Science and Biotechnology, College of Medical Science and Technology, Taipei Medical University, No. 301, Yuantong Rd., Zhonghe Dist., New Taipei City, 235, Taiwan.
Abstract:
Candida albicans is a major opportunistic pathogen, responsible for nearly half of clinical candidemia cases. The rising prevalence of azole-resistant Candida species represents a significant clinical challenge, underscoring the urgent need for alternative therapeutic strategies. Monoclonal antibody-based therapies have emerged as a promising and cost-effective approach to combating Candida infections. Agglutinin-like sequence protein 3 (Als3), a key cell surface protein of C. albicans, plays a pivotal role in adherence and biofilm formation, both of which are essential for its pathogenesis. In this study, recombinant Als3 protein was purified and utilized to immunize chickens, resulting in the production of Als3-specific immunoglobulin Y (IgY) antibodies. Two single-chain variable fragment (scFv) antibody libraries were subsequently constructed using phage display technology, yielding transformant counts of 5.3 × 107 and 2.8 × 107, respectively. Phage-based enzyme-linked immunosorbent assay (ELISA) revealed enhanced signals following bio-panning, enabling the identification and sequence validation of three scFv antibodies. These scFv antibodies exhibited strong binding activities to Als3, as confirmed through ELISA and western blot analyses. Binding affinities were determined to be ~ 10⁻⁸ M via serial titration ELISA and competitive ELISA. Additionally, the selected scFv antibodies specifically recognized endogenous Als3 protein in C. albicans, as demonstrated by western blot and cell-based ELISA assays. In conclusion, this study successfully generated and characterized high-affinity scFv antibodies targeting Als3, which exhibited exceptional specificity and binding activity. These findings highlight their potential as promising immunotherapeutic candidates for the treatment of C. albicans infections. KEY POINTS: • The Als3 protein of C. albicans is a critical biomarker and therapeutic target • Chicken-derived scFv antibodies against Als3 were developed via phage display • The scFv antibodies showed strong binding to endogenous Als3 in C. albicans.
Insights
Researchers developed chicken-derived single-chain variable fragment (scFv) antibodies targeting Candida albicans Als3 protein. These antibodies show high affinity and specificity, offering potential for new immunotherapies against C. albicans infections.
Area of Science:
- Immunology and Microbiology
- Biotechnology and Antibody Engineering
Background:
- Candida albicans is a significant opportunistic pathogen causing candidemia, with increasing azole resistance posing a clinical challenge.
- Agglutinin-like sequence 3 (Als3) is a crucial cell surface protein in C. albicans, vital for adherence and biofilm formation during infection.
- Monoclonal antibody therapies present a promising avenue for developing novel treatments against C. albicans infections.
Purpose of the Study:
- To generate and characterize high-affinity single-chain variable fragment (scFv) antibodies targeting the Als3 protein of Candida albicans.
- To evaluate the specificity and binding capabilities of these novel scFv antibodies for potential immunotherapeutic applications.
Main Methods:
- Recombinant Als3 protein was used to immunize chickens, producing Als3-specific immunoglobulin Y (IgY) antibodies.
- Two single-chain variable fragment (scFv) antibody libraries were constructed using phage display technology.
- Phage-based ELISA and bio-panning were employed to identify and validate scFv antibodies with high binding affinity to Als3.
Main Results:
- Three scFv antibodies were successfully identified, demonstrating strong binding activity to Als3 via ELISA and western blot.
- The selected scFv antibodies exhibited high binding affinities, in the range of approximately 10⁻⁸ M.
- These scFv antibodies specifically recognized endogenous Als3 protein in C. albicans, confirmed by western blot and cell-based ELISA.
Conclusions:
- This study successfully generated high-affinity, specific scFv antibodies targeting the C. albicans Als3 protein.
- The characterized scFv antibodies hold significant potential as immunotherapeutic agents for treating C. albicans infections.
- Als3 serves as a critical biomarker and therapeutic target for developing novel anti-Candida strategies.
More Related Videos
09:12A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection
Published on: June 15, 2018
06:50A Soluble Tetrazolium-Based Reduction Assay to Evaluate the Effect of Antibodies on Candida tropicalis Biofilms
Published on: September 16, 2022